for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Momenta Pharmaceuticals, Inc.

MNTA.O

Latest Trade

32.21USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.04

 - 

39.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Momenta Announces Positive Topline Data From Interim Analysis Of Phase 2 Vivacity-MG Study Of Nipocalimab (M281)

* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA FROM INTERIM ANALYSIS OF PHASE 2 VIVACITY-MG STUDY OF NIPOCALIMAB (M281) IN GENERALIZED MYASTHENIA GRAVIS (GMG)

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.34

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS

BRIEF-Momenta Provides Corporate Update Amid Covid-19 Pandemic

* MOMENTA PHARMACEUTICALS INC - DOES NOT INTEND TO PAUSE ENROLLMENT OF PHASE 2 CLINICAL STUDY OF NIPOCALIMAB

Toyota partners with China's Momenta on high definition maps for autonomous cars

Japanese automaker Toyota Motor Corp has partnered with Chinese autonomous driving startup Momenta to develop a high definition (HD) mapping platform in China for autonomous driving vehicles, Momenta said in a statement.

Momenta, Amphastar settle generic Lovenox drug patent case

Amphastar Pharmaceuticals Inc on Wednesday said Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.

BRIEF-Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

* AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ

Fed Circuit dismisses Momenta Pharmaceuticals patent appeal as moot

A federal appeals court on Thursday dismissed as moot a challenge by Momenta Pharmaceuticals Inc to a Bristol-Myers Squibb Inc patent for treating immune system disorders, saying Momenta had no legally protected interest in the patent.

Amphastar cannot collect $100 mln during Momenta drug patent appeal - judge

A federal judge on Monday ruled that Amphastar Pharmaceuticals Inc must wait to collect a $100 million bond that Momenta Pharmaceuticals Inc and Sandoz Inc posted in a drug patent case it won until after an appellate court hears the dispute.

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.63

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18

* MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML

BRIEF-Momenta Pharmaceuticals Announces Positive Outcome For Contracted Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME FOR CONTRACTED GLATOPA (GLATIRAMER ACETATE INJECTION) FILL/FINISH MANUFACTURER Source text for Eikon: Further company coverage:

BRIEF-Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However

* MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING Source text:(http://bit.ly/2CTkx5R) Further company coverage:

BRIEF-Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof Of Mechanism For M281

* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up